Related Experiment Video
Updated: Jul 20, 2026
06:00
Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
Published on: September 13, 2017
mTOR function and therapeutic targeting in breast cancer
Stephen H Hare1, Amanda J Harvey1
1Institute for Environment Health and Societies, Brunel University London Uxbridge, UB8 3PH, United Kingdom.
American Journal of Cancer Research
|April 13, 2017
Summary
The mechanistic target of rapamycin (mTOR) pathway is crucial in cancer. Rapamycin analogs show promise but have drawbacks, leading to research into new mTOR inhibitors for better cancer treatment.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- The mechanistic target of rapamycin (mTOR) pathway is a key regulator of cell growth and metabolism.
- Dysregulation of mTOR signaling is implicated in various cancers, including breast cancer.
- mTOR exists in two complexes, mTORC1 and mTORC2, with distinct functions.
Purpose of the Study:
- To review the role of the mTOR pathway in cancer.
- To discuss the therapeutic potential and limitations of rapamycin analogs (rapalogues) in cancer treatment.
- To highlight the development of novel mTOR inhibitors.
Main Methods:
- Literature review of mTOR pathway research.
- Analysis of clinical data on rapalogue efficacy and side effects.
- Exploration of emerging mTOR inhibitor mechanisms.
Main Results:
- Rapamycin and its analogs primarily inhibit mTORC1, slowing tumor growth.
- Everolimus is approved for specific advanced breast cancer cases.
- Rapalogues can activate counteracting feedback pathways, limiting their effectiveness.
Conclusions:
- mTOR inhibition is a validated cancer treatment strategy.
- New ATP-competitive mTOR inhibitors are being developed to overcome rapalogue limitations.
- Targeting the mTOR pathway remains a significant area of cancer drug discovery.
Related Concept Videos
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...